scispace - formally typeset
M

Masato Minami

Researcher at Osaka University

Publications -  266
Citations -  4944

Masato Minami is an academic researcher from Osaka University. The author has contributed to research in topics: Lung cancer & Lung transplantation. The author has an hindex of 35, co-authored 249 publications receiving 4318 citations. Previous affiliations of Masato Minami include Canon Inc. & University of Texas Southwestern Medical Center.

Papers
More filters
Journal ArticleDOI

Clinical Spectrum of Mediastinal Cysts

TL;DR: The institutional experience with congenital cysts of the mediastinum was reviewed, emphasizing the clinical spectrum of the disease and MRI has become a useful tool for providing supplemental data in combination with CT.
Journal ArticleDOI

Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma

TL;DR: Patients with unilateral metastasis and Dukes' A for the primary tumor benefit most from the resection of pulmonary metastasis from colorectal carcinoma, and the number of metastases, prethoracotomy CEA level, and hilar or mediastinal lymph-node involvement should be considered to determine the operative indication.
Journal ArticleDOI

Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution.

TL;DR: The authors' institutional experience of mediastinal GCT is reviewed, emphasizing the clinical spectrum, time trends of treatment, and recent advances in therapeutic modalities for malignant GCT.
Journal ArticleDOI

IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling.

TL;DR: IL‐6 may contribute to maintenance of a paracrine loop that functions as part of the communication between CAFs and NSCLC cells, resulting in chemoresistance.
Journal ArticleDOI

Long-term outcomes after a variety of video-assisted thoracoscopic lobectomy approaches for clinical stage IA lung cancer: A multi-institutional study

TL;DR: V VATS lobectomy, a safe procedure with earlier return to normal activities, can be regarded as an acceptable cancer operation for the patients with peripheral non-small cell lung cancer less than or equal to 2 cm in diameter with the same long-term survivals as open surgery.